Discovery and validation of biomarkers for Parkinson's disease from human cerebrospinal fluid using mass spectrometry-based proteomics analysis.

ABSTRACT:

Background

Proteomic biomarkers for Parkinson's disease (PD) are critical for identifying new targets for disease-modifying therapies and expanding our understanding of disease pathophysiology.

Methods

Deep proteome analysis of a cerebrospinal fluid (CSF) cohort (40 PD, 40 controls) coupled with previous data from the substantia nigra (SN) proteome was used to discover low abundance biomarkers involved in PD pathogenesis. We validated our findings using parallel reaction monitoring mass spectrometry with an independent cohort of CSF samples (80 PD, 80 controls). We further evaluated our biomarkers with a separate cohort of 80 individuals with Dementia with Lewy Bodies (DLB). We then correlated our candidate biomarkers with motor and cognitive performance.

Findings

We

SUBMITTER: Oh S 

PROVIDER: S-EPMC12368294 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature